Caelyx (liposomal doxorubicin) and carboplatin

Indication
Relapsed ovarian cancer that is partially platinum sensitive between 2-12 months following relapse OR patients with significant residual neuropathy from previous treatment

Contraindication
Hypersensitivity to peanut or soya

Regimen details

DRUG	FLUID	TIME
Caelyx 30mg/m²	250mls 5% Glucose	1 hour
Carboplatin AUC 5	500mls 5% Glucose	1 hour

Cycle frequency
Repeat every 4 weeks for 6 cycles

Number of cycles
6 cycles

Emetogenicity
Moderate

Extravasation
Carboplatin- irritant
Liposomal Doxorubicin- exfoliant

Investigations – pre-first cycle

Investigation	Validity period
FBC	14 days
U+Es (including creatinine clearance)	14 days
LFTs	14 days
CA1250	14 days

Cautions
The Calvert formula is not considered reliable if the creatinine clearance is <40 ml/min. However, prescribing according to surface area leads to excessive doses. Therefore, even in those patients with renal impairment the Calvert formula will be used and doses modified subsequently up or down depending on blood counts

Investigations – pre-subsequent cycles

Consultation needed prior to each cycle

FBC	
U&Es	If serum creatinine raised >20% repeat calculated creatinine clearance before the next cycle
CA125	To be retrospectively looked at
LFTs	The liver function test may be retrospectively looked at (i.e. after the chemotherapy treatment) unless they are known to be abnormal then they need to be repeated the day before so that the results are available pre-chemotherapy

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit	Action
Neutrophil count	> 1.5 x 10^9/L	Proceed, if anaemic transfuse
Platelet count	> 100 x 10^9/L	Proceed, if anaemic transfuse
Neutrophil count	1.2 – 1.5 10^9/L	Contact **consultant**

Delay treatment by **1 week** if outside these limits and inform **consultant**

Dose modifications

20% dose reduction if there is **a delay >1 week,** if there has been a previous delay of more than 2 cycles or if the patient experiences neutropenic sepsis

Adverse effects

- Hypersensitivity reactions (usually after > 6 cycles)
- Alopecia (very occasionally)
- Nausea and vomiting
- Bone marrow suppression
- Flushing effects
- Myelosuppression
- Hand-foot syndrome
- Stomatitis

For full details consult product literature/ reference texts

THIS PROTOCOL HAS BEEN DIRECTED BY DR MOON, DESIGNATED LEAD CLINICIAN FOR GYNAECOLOGICAL CAJCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE: April 2022
REVIEW: April 2024
VERSION: 13
